Damora Therapeutics, Inc. Common Stock (DMRA) is a publicly traded the market company. As of July 17, 2026, DMRA trades at $31.11 with a market cap of $1.91B and a P/E ratio of 0.00. DMRA moved +2.30% today. Year to date, DMRA is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $16.50 to $31.77. Analyst consensus is strong buy with an average price target of $42.67. Rallies surfaces DMRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for DMRA, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $31.11 |
| Market Cap | $1.91B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $31.77 |
| 52-Week Low | $16.50 |
| Volume | 131.84K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
7 analysts cover DMRA: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $42.67.